BRAF V600EPhase 3 RCTNEJM 2019來源:人工整理
EC ± binimetinib vs cetux+chemo
關鍵結果mOS 9.0 vs 5.4 mo, HR 0.52
首次證實 BRAF+EGFR 雙阻斷在 2L+ BRAF V600E mCRC 的 OS 獲益
詳細證據整理
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Abstract
Design: Phase 3 randomized trial enrolling 665 patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had progressed after 1-2 prior regimens in the metastatic setting.
Arms: Patients were randomized 1:1:1 to:
- Triplet: encorafenib + binimetinib + cetuximab
- Doublet: encorafenib + cetuximab
- Control: cetuximab + irinotecan or FOLFIRI
Key Results (Interim Analysis)
| Endpoint | Triplet | Doublet | Control |
|---|---|---|---|
| Median OS | 9.0 months | 8.4 months | 5.4 months |
| OS HR vs Control | 0.52 (P<0.001) | 0.60 | -- |
| ORR | 26% | -- | 2% |
| ORR P-value | P<0.001 (Triplet vs Control) | ||
| Grade ≥3 AEs | 58% | 50% | 61% |
Conclusions
The triplet combination of encorafenib, binimetinib, and cetuximab, as well as the doublet of encorafenib plus cetuximab, resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with BRAF V600E-mutant mCRC. This was the first demonstration of survival benefit for a chemotherapy-free targeted regimen in biomarker-selected patients with mCRC.
本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。
讀者討論
讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。
載入留言中…